Charm Therapeutics
Charm is using deep-learning models via its proprietary platform, DragonFold, to predict the co-crystal structure of a protein-ligand complex based on a protein's primary sequence and the ligand’s chemical structure.
Charm Therapeutics has raised €116M across 2 funding rounds from 9 investors, most recently a Series B round in Sep 2025. Based in London, UK; active in AI. Data as of 28 Oct 2026.
London, UKcharmtx.com ↗
Total raised
€116M
€115,961,029
Funding rounds
2
Investors
9
distinct backers
Active since
2022-06
latest 2025-09
Funding by year
EUR raised per yearCharm Therapeutics — funding by year — interactive chart.
Data table
| Charm Therapeutics — funding by year | |
|---|---|
| 2022 | €47M |
| 2025 | €69M |
Signals
High confidenceRaise-next likelihood73
base rate 48% for Series B
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood19
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-02 | Series B | €69M | F-Prime Capital,Khosla Ventures,New Enterprise Associates (NEA),Nvidia,OrbiMed,SR One | View deal → |
| 2022-06-10 | Series A | €47M | Axial,Braavos Capital,F-Prime Capital,General Catalyst,Khosla Ventures,OrbiMed | View deal → |